NAT2 fast acetylator genotype seemed to be protective against lung cancer in light smokers and not among heavy smokers

No evidence of an overall association of NAT2 gene polymorphisms to either colon or lung cancer risk.

NAT2 polymorphisms are associated with lung cancer

Opposite effects of NAT2 gene polymorphisms on the risk of lung cancer are possible.

NAT2 polymorphisms is associated with lung cancer with wildtype EGFR.

For NAT2 gene, the results suggest a role for the low acetylator phenotype in the development of colon and lung cancer, especially in females

Findings suggest that the influence of NAT2 genotype, alone or in combination with p53 genotype, may confer increased susceptibility to lung cancer.

Results suggest that GSTM1 and NAT2 genotypes play an independent and interactive role in the formation of carcinogen DNA adduct in the lung.

little evidence of an association between the NAT2 polymorphism and the risk of lung cancer (Meta-analysis)

Among patients with small cell lung cancer, there was no predominance of genotype of acetylation, whereas among patients with non-small cell lung cancer predominated NAT2*5/5 and NAT2*5/6 genotypes (slow acetylators).

Epidemiological studies suggest that the NAT1 and NAT2 acetylation polymorphisms modify the risk of developing cancers of the urinary bladder, colorectal, breast, head and neck, and lung

NAT2 rs1799930 polymorphism is an important factor of lung squamous carcinoma resistance in Chinese smoking males.

Disequilibrium distribution of NAT2 polymorphism was found in lung cancer patients among Han and Mongolian populations.

Polymorphic variants of GSTP1,GSTM1,GSTP1, and NAT2 genes were accociated with development of occupational lung cancer.

TT genotype in NAT2 C282T polymorphism may be a risk factor for lung cancer susceptibility. Additionally, the acetylator status of 5 SNPs in NAT2 gene may not be associated with lung cancer risk (Meta-Analysis)